Article citationsMore>>

Thatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E.H., Pemberton, K., Archer, V., et al. (2005) Gefitinib Plus Best Supportive Care in Previously-treated Patients with Refractory Advanced Non-small-cell Lung Cancer: Results from a Randomised, Placebo-Controlled, Multicentre Study (Iressa Survival Evaluation in Lung Cancer). Lancet, 366, 1527-1537.
https://doi.org/10.1016/S0140-6736(05)67625-8

has been cited by the following article:

• TITLE: The Impact of Chemotherapy on EGFR Mutation Status in Non-Small-Cell Lung Cancer: A Meta-Analysis

  AUTHORS: Xiaoshun Shi, Fuxi Huang, Allen M. Chen, Zhuolin Wu, Qianqian Huang, Ying Liang, Qipeng Zhou, Haiyun Mo, Xiaoxiang Li, Jiexia Zhang

  KEYWORDS: EGFR Mutation, Chemotherapy, Non-Small Cell Lung Cancer, Me-ta-Analysis

  JOURNAL NAME: Open Journal of Genetics, Vol.7 No.4, December 21, 2017

  ABSTRACT: Background: Emerging evidence indicates that chemotherapy for lung cancer may alter EGFR mutation status. However, whether chemotherapy as a firstline treatment may increase or reduce the frequency of EGFR mutations in NSCLC remains uncertain. Therefore, we conducted a meta-analysis to evaluate whether chemotherapy leads to altered EGFR mutation status. Methods: A systematic literature search was performed using the PubMed, OVID, Science Direct, Cochrane Library, and CNKI databases for studies on pre- and post-chemotherapy EGFR mutation status. Relevant studies documenting perichemotherapy EGFR mutation ratios were included. Analyses of pooled odds ratios (OR) were performed. Results: Six studies involving 656 patients were included in this meta-analysis. It was found that chemotherapy may alter EGFR status (OR = 1.93, 95% CI 1.05 - 3.56; p Conclusions: Chemotherapy may contribute to altered EGFR status. NSCLC patients with EGFR mutations might need to be considered for EGFR status redeterminations prior to second-line EGFR-TKI treatment or upon tumor recurrence after chemotherapy. Further randomized clinical trials should investigate the impact of neoadjuvant or first-line chemotherapy on EGFR mutation status in NSCLC patients.